XNW7201

The main objectives of Phase I are: 1) to evaluate the safety and tolerability of oral administration of XNW7201 tablets in Chinese patients with advanced solid tumors; 2) to explore the dosage for subsequent clinical studies. Secondary objectives: 1) to evaluate the pharmacokinetic characteristics of XNW7201 tablets in Chinese patients with advanced solid tumors; 2) to preliminarily evaluate the anti-tumor activity of XNW7201 tablets in Chinese patients with advanced solid tumors; 3) to evaluate the pharmacodynamic characteristics of XNW7201 tablets in Chinese patients with advanced solid tumors. The main objectives of Phase IIa are: 1) to evaluate the anti-tumor efficacy of XNW7201 tablets in selected subjects with advanced malignant tumors (including patients with colorectal cancer and esophageal cancer of specific genotypes). Secondary study objectives: 1) to further evaluate the safety of XNW7201 tablets in patients with advanced malignant tumors; 2) to evaluate the pharmacokinetic characteristics of XNW7201 tablets in patients with advanced malignant tumors; 3) to evaluate the pharmacodynamic characteristics of XNW7201 tablets in patients with advanced malignant tumors. Exploratory objectives: 1) To explore potential biomarkers associated with XNW7201 tablets treatment (including but not limited to the following gene abnormalities: RNF43 mutation, ZNRF3 mutation, R-spondin (RSPO) gene overexpression, RAS mutation or gene copy number amplification or overexpression, Notch mutation, and other WNT pathway-related gene abnormalities); 2) To explore the types of metabolites and the concentrations of major metabolites (other metabolites besides M4 and M7) in plasma after oral administration of XNW7201 tablets.